Multi-target Hi-TCR-T Cells therapy (Eastern Hepatobiliary Surgery Hospital)

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameMulti-target Hi-TCR-T Cells therapy (Eastern Hepatobiliary Surgery Hospital)
Drug Alias NameSuper Hi-TCR-T (Eastern Hepatobiliary Surgery Hospital)Super Hi-TCR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsCD276 antigen modulatorsFibroblast activation protein alpha modulators +[7] 
TargetsCD276 antigenProlyl endopeptidase FAPGlypican-3 +[6] 
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Oriental Hepatobiliary Surgery Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Oriental Hepatobiliary Surgery Hospital
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A